BriaCell Therapeutics Corp.

BriaCell’s Chief Medical Officer, Dr. Giuseppe Del Priore, shares insights on the Company's clinical data being presented at the upcoming 2024 San Antonio Breast Cancer Symposium? (SABCS?). Read more: https://bit.ly/3Ze4xCO #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

Saranya Chumsri, M.D., Principal Investigator and Professor of Oncology, Mayo Clinic, commented on the impressive clinical data in the BriaCell pivotal Phase 3 study across all #breastcancer subtypes. https://bit.ly/3Ze4xCO #SABCS24 #metastaticbreastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

President & CEO, Dr. William V. Williams, comments on BriaCell's ongoing commitment to finding therapeutic options for difficult-to-treat #metastaticbreastcancer patients. Read more: https://bit.ly/3Ze4xCO #SABCS24 #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) will highlight its positive overall survival and clinical benefit data in metastatic breast cancer (MBC) patients who were treated with the Bria-IMT? plus checkpoint inhibitor (CPI) combination in its “Spotlight” poster presentation session, at the 2024 San Antonio Breast Cancer Symposium? (SABCS?). Find details: https://bit.ly/3Ze4xCO #SABCS24 #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

BriaCell’s President and CEO, Dr. William V. Williams, emphasizes the significant potential of our personalized and off-the-shelf cancer therapy, Bria-OTS? in patients with melanoma, prostate and lung cancers. Learn more: https://bit.ly/3V1asJY #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

BriaCell's five poster presentations at #SABCS24 will highlight updated survival and key biomarker data from our Phase 2 trial of Bria-IMT? plus immune check point inhibitor in #metastaticbreastcancer. For more details, please visit: https://bit.ly/3NRgOaH #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

BriaCell’s Chief Medical Officer, Dr. Giuseppe Del Priore, addresses the significance of the first patient dosed with Bria-OTS?, marking a major milestone for the company and cancer patients alike. Read more: https://bit.ly/3V1asJY #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

Sant P. Chawla, MD, FRACP, Head of the Sarcoma Oncology Center in Santa Monica, CA, and Principal Investigator for the Bria-OTS? study is looking forward to helping develop BriaCell's novel platform with the goal of improving patient outcomes. Find more information: https://bit.ly/3V1asJY #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatment

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) announced that the first patient was dosed in its Phase 1/2 study (ClinicalTrials.gov identifier: NCT06471673) to evaluate the safety and efficacy of Bria-OTS?, BriaCell’s personalized next generation immunotherapy. The study will investigate Bria-OTS? alone and in combination with immune check point inhibitor tislelizumab? (manufactured and supplied by BeiGene, Ltd.) for the treatment of metastatic breast cancer. Find details: https://bit.ly/3V1asJY #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

BriaCell's upcoming #SABCS24 presentations include planned Phase 3 study design expanding use of Bria-IMT? + CPI to any cancer patient with central nervous system (CNS) metastases. https://bit.ly/3NRgOaH #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs